Search Results
Sep 03, 2026, 01:31 ET EpiVax ने प्रतिरक्षाजनत्व पूर्वानुमान के लिए AI-संवर्धित मॉडल लॉन्च किए
जिससे इन सिलिको प्रतिरक्षाजनत्व जोखिम आकलन की प्रासंगिकता और पूर्वानुमानित मूल्य में सुधार होता है। ये सुधार मानव-प्रासंगिक नई दृष्टिकोण पद्धतियों (NAMs) को अपनाने को बढ़ावा देने वाली हालिया FDA पहलों के साथ निकटता से मेल खाने के साथ-साथ प्रायोजकों को प्रतिरक्षा संबंधी समस्याओं की पहचान तथा एसेट वैल्यू
More news about: EpiVax, Inc.
Sep 03, 2026, 01:22 ET EpiVax führt KI-gestützte Modelle zur Vorhersage der Immunogenität ein
stehen in engem Einklang mit den jüngsten Initiativen der FDA zur Förderung der Einführung von für den Menschen relevanten „New Approach Methodologies" (NAMs) und helfen den Sponsoren gleichzeitig dabei, immunologische Risiken zu identifizieren, den Wert ihrer Vermögenswerte zu schützen und Entwicklungsprogramme
More news about: EpiVax, Inc.
Sep 02, 2026, 11:16 ET EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
immunogenicity risk assessments. The enhancements align closely with recent FDA initiatives advancing the adoption of human-relevant New Approach Methodologies (NAMs), while helping sponsors identify immune liabilities, protect asset value, and de-risk development programs. About EpiVax
More news about: EpiVax, Inc.
Sep 02, 2026, 11:04 ET EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
immunogenicity risk assessments. The enhancements align closely with recent FDA initiatives advancing the adoption of human-relevant New Approach Methodologies (NAMs), while helping sponsors identify immune liabilities, protect asset value, and de-risk development programs. About EpiVax
More news about: EpiVax, Inc.
Aug 27, 2026, 08:30 ET Assessing the Use of Non-Human Primates in Translational Research Today, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how non-human primate (NHP) models are used in translational research alongside new approach methodologies (NAMs). The featured panelists will compare NHP models with emerging alternatives and examine how scientific, ethical and regulatory factors inform model selection.
More news about: Xtalks
Aug 19, 2026, 09:14 ET XtalPi Holdings Announces 2026 Interim Results
key delivery milestone. As one of the first companies to participate in the CDE's multicenter collaborative validation of new approach methodologies (NAMs), Xellar Biosystems was selected for the "Pioneer Program" and is also advancing model qualification under the U.S. FDA's ISTAND program. Xellar Biosystems
More news about: XtalPi Holdings Limited
Aug 06, 2026, 08:30 ET Navigating the Shift from Animal Testing to NAMs in Drug Development, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how evolving FDA policies and New Approach Methodologies (NAMs) are changing the role of animal testing in drug development. The featured speakers will examine the regulatory direction, the benefits and challenges of reduced-animal testing strategies and the implications
More news about: Xtalks
Aug 04, 2026, 08:00 ET Xtalks Announces its Life Science Webinar Calendar for August 2026
RESEARCHAug 26 - Accelerate Translational Research with Quantitative Image AnalysisAug 27 - Navigating the Shift from Animal Testing to NAMs in Drug DevelopmentABOUT XTALKSXtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare
More news about: Xtalks
Jul 29, 2026, 07:00 ET PBS Biotech Joins Organoid COMMONS to Accelerate Industrialization and Scalability of Human-Relevant Models
innovation and industrial adoption. By uniting key stakeholders across the biotechnology ecosystem, the consortium aims to refine New Approach Methodologies (NAMs) and deliver high-quality, highly reproducible human-relevant models—reducing the pharmaceutical industry's reliance on animal models.PBS Biotech
More news about: PBS Biotech Inc.
Jul 26, 2026, 13:59 ET NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)
Niederlande, MIAMI und FLORENZ, Italien, 26. Juli 2026 /PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS oder „NewAmsterdam" oder das „Unternehmen"), ein biopharmazeutisches Unternehmen in der späten klinischen Entwicklungsphase, das orale, nicht auf Statinen
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 25, 2026, 13:39 ET NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
Pays-Bas, MIAMI et FLORENCE, Italie, 25 juillet 2026 /PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq : NAMS (ou « NewAmsterdam » ou la « Société »), une société biopharmaceutique spécialisée dans les essais cliniques de phase avancée qui développe des médicaments
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 12:57 ET NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®
MIAMI y FLORENCIA, Italia, 24 de julio de 2026 /PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS o "NewAmsterdam" o la "Compañía"), una compañía biofarmacéutica en fase clínica avanzada que desarrolla medicamentos orales no estatínicos para pacientes
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 10:13 ET NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Netherlands and MIAMI and FLORENCE, Italy, July 24, 2026 /PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 23, 2026, 09:05 ET AcroCyte Therapeutics Awarded ARPA ‑H Funding to Advance Scalable Human Organoid Technologies
Therapeutics Inc.AcroCyte Therapeutics Inc. is a biotechnology company dedicated to addressing key challenges in New Approach Methodologies (NAMs) by enabling reproducible, robust, and scalable human‑relevant model systems. Through its organoid platforms, the company is advancing animal‑free,
More news about: AcroCyte Therapeutics Inc.
Jul 22, 2026, 11:20 ET Economic Analysis of the Chemo Mouthpiece® Medical Device Suggests Potential Cost Savings of Over $15,000 per Patient Receiving Chemotherapy and Reduced Healthcare Resource Utilization
Designation in December 2021 and the device was FDA 510(k) cleared in January 2024.Chemo Mouthpiece Market Access National Account Managers (NAMs) continue to actively engage key stakeholders across the U.S. payer landscape. They are presenting the Chemo Mouthpiece's value proposition and advancing
More news about: Chemomouthpiece, LLC
Jul 13, 2026, 09:16 ET HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
pathology, immune phenotyping, biomarkers and translational interpretation.AI and NAMs help design smarter in vivo studiesHKEY-AI-NAM-Bridge™ 1.0 is based on a practical principle: AI and NAMs do not simply replace animal studies; they can help design more targeted and more interpretable
More news about: HKeyBio
Jul 07, 2026, 03:24 ET New7Wonders Honours the Official 7 Wonders Day this year in Viet Nam
iconic locations: Ha Long Bay, internationally recognised as one of the New 7 Wonders of Nature, and Ha Noi, and is being supported by Vingroup, Viet Nam's leading private enterprise, and VTV, the country's national television broadcaster, ensuring nationwide engagement and coverage.As the centrepiece
More news about: New7Wonders
Jul 07, 2026, 03:19 ET New7Wonders Honours the Official 7 Wonders Day this year in Viet Nam
iconic locations: Ha Long Bay, internationally recognised as one of the New 7 Wonders of Nature, and Ha Noi, and is being supported by Vingroup, Viet Nam's leading private enterprise, and VTV, the country's national television broadcaster, ensuring nationwide engagement and coverage.As the centrepiece
More news about: New7Wonders
Jun 24, 2026, 09:32 ET EpiVax ने प्रयोगशाला विस्तार और सुव्यवस्थित, NAM-केंद्रित इन-विट्रो सेवाएं घोषित की
में विस्तार हुआ है। यह निवेश, मानव-प्रासंगिक प्रतिरक्षाजनकता के जोखिम का मूल्यांकन करने के लिए एकीकृत, मानव-प्रासंगिक, नए दृष्टिकोण की कार्यविधियों (NAMs) की बढ़ती मांग को दर्शाता है, क्योंकि पारंपरिक पशु मॉडल मानव-प्रासंगिक प्रतिरक्षाजनकता संबंधी परिणाम प्रदान करने में असमर्थ हैं।
More news about: EpiVax, Inc.
Jun 23, 2026, 15:16 ET EpiVax kündigt Laborerweiterung und optimierte, auf NAM ausgerichtete In-vitro-Dienstleistungen an
immunologischer Tests erweitert wurden. Diese Investition spiegelt die wachsende Nachfrage nach integrierten, menschenrelevanten Methoden des „New Approach" (NAMs) zur Bewertung des Immunogenitätsrisikos wider, da herkömmliche Tiermodelle nur begrenzt menschenrelevante Immunogenitätsergebnisse liefern können.
More news about: EpiVax, Inc.
Jun 23, 2026, 09:12 ET EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
capacity to support advanced immunological testing. This investment reflects growing demand for integrated, human-relevant, new approach methodologies (NAMs) to evaluate immunogenicity risk due to limitations of traditional animal models to provide human-relevant immunogenicity readouts.
More news about: EpiVax, Inc.
Jun 23, 2026, 09:12 ET EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
capacity to support advanced immunological testing. This investment reflects growing demand for integrated, human-relevant, new approach methodologies (NAMs) to evaluate immunogenicity risk due to limitations of traditional animal models to provide human-relevant immunogenicity readouts.
More news about: EpiVax, Inc.
Jun 22, 2026, 07:00 ET Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation
PlasmonicTron standardizes large human 3D organoid production for industrial NAMs.Taiwan Universe BioMedicine
More news about: BPIPO
Jun 15, 2026, 08:55 ET Scientist.com to Host Expert Webinar on New Approach Methodologies for Drug Discovery and Development
BIOIVT, HUB ORGANOIDS AND CYPROTEX TO SHARE PRACTICAL STRATEGIES FOR APPLYING HUMAN-RELEVANT MODELS, ORGANOIDS, AI-ENABLED TRANSCRIPTOMICS AND OTHER NAMS ACROSS RESEARCH WORKFLOWSSAN DIEGO, June 15, 2026 /PRNewswire/
More news about: Scientist.com
Jun 09, 2026, 12:42 ET Critical Path Institute to Convene Drug Development Leaders at 2026 Global Impact Conference
breakouts addressing lived experience and the regulatory context across therapeutic areas, and discussions on advancing new approach methodologies (NAMs) as drug development tools.Additionally, on Thursday, Sept. 17, C-Path will convene a dedicated working session on C-Path's
More news about: Critical Path Institute